A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. by George F Wohlford, Leo F Buckley, Dinesh Kadariya, Taeshik Park, Juan Guido Chiabrando, Salvatore Carbone, Virginia Mihalick, Matthew S Halquist, Adam Pearcy, Dana Austin, Cohava Gelber, Antonio Abbate, Benjamin Van Tassell

Get full text